The latest price target for Nurix Therapeutics (NASDAQ:NRIX) was reported by Morgan Stanley on February 3, 2025. The analyst firm set a price target for $17.00 expecting NRIX to rise to within 12 months (a possible 0.47% upside). 42 analyst firms have reported ratings in the last year.

The latest analyst rating for Nurix Therapeutics (NASDAQ:NRIX) was provided by Morgan Stanley, and Nurix Therapeutics maintained their equal-weight rating.

The last upgrade for Nurix Therapeutics Inc happened on May 31, 2022 when Wells Fargo raised their price target to $25. Wells Fargo previously had an equal-weight for Nurix Therapeutics Inc.

There is no last downgrade for Nurix Therapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Nurix Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Nurix Therapeutics was filed on February 3, 2025 so you should expect the next rating to be made available sometime around February 3, 2026.

While ratings are subjective and will change, the latest Nurix Therapeutics (NRIX) rating was a maintained with a price target of $16.00 to $17.00. The current price Nurix Therapeutics (NRIX) is trading at is $16.92, which is within the analyst’s predicted range.